Sign In
Buy URGN
$26.60
+0.0600 (+0.226%)
At Close: Jun 03, 2026
UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates
08:30am, Tuesday, 25'th Nov 2025
UroGen Pharma (URGN) is rated a Strong Buy, with a $33/share price target by end of 2026, driven by its proprietary RTGel technology. URGN's newly approved Zusduri targets a large bladder cancer marke
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
08:00am, Tuesday, 25'th Nov 2025
PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and speci
UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript
10:26pm, Thursday, 06'th Nov 2025
UroGen Pharma Ltd. ( URGN ) Q3 2025 Earnings Call November 6, 2025 10:00 AM EST Company Participants Vincent Perrone - Senior Director of Investor Relations Elizabeth Barrett - President, CEO & Direct
Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates
10:16am, Thursday, 06'th Nov 2025
Urogen Pharma (URGN) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.55 per share a year ago.
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
08:00am, Thursday, 06'th Nov 2025
Reported three-month complete response rate of 77.8% from the Phase 3 UTOPIA trial of UGN-103, consistent with ENVISION results; FDA agreed to regulatory plan to submit an NDA based on data from the U
PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and speci
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
08:00am, Tuesday, 04'th Nov 2025
PRINCETON, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
Urogen Pharma (URGN) Projected to Post Quarterly Earnings on Thursday
03:02am, Tuesday, 04'th Nov 2025
Urogen Pharma (NASDAQ: URGN - Get Free Report) is anticipated to issue its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.70
UroGen: Expect Rough Patch Before Strong Recovery In 2026
08:36am, Sunday, 02'nd Nov 2025
UroGen Pharma is revisited after a previous Strong Buy rating, with UroGen having increased ~95% since then. The article reflects on UroGen's RTGel technology, which supports JELMYTO and ZUSDURI, its
UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
08:00am, Thursday, 30'th Oct 2025
Conference Call and Webcast Scheduled for Thursday, November 6th, 2025, at 10:00 AM ET Conference Call and Webcast Scheduled for Thursday, November 6th, 2025, at 10:00 AM ET
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
11:07am, Wednesday, 29'th Oct 2025
Urogen Pharma (URGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
08:00am, Monday, 27'th Oct 2025
PRINCETON, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
PRINCETON, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Monday, 08'th Sep 2025
PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Pharma to Present at Upcoming Investor Conferences
08:00am, Thursday, 21'st Aug 2025
PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
